State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.
State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.
复制标题
DOI：
10.1007/s12170-014-0430-5
复制
发表时间：
2015-01
影响因子：
1.9
通讯作者：
McGuire DK
中科院分区：
文献类型：
--
作者：
Kumbhani DJ;Marso SP;Alvarez CA;McGuire DK
糖尿病是一种全球性流行病，与心血管疾病的高负担相关。糖尿病患者存在多种血小板紊乱，抗血小板药物仍然是糖尿病患者二级预防和高危一级预防的一线药物。本文综述了糖尿病患者口服抗血小板药物的低反应性，特别是阿司匹林和氯吡格雷抵抗。讨论的主题包括抗血小板测试，用于定义低反应和抵抗的定义，其患病率，与临床结果的关联以及减轻抵抗的策略。普拉格雷和替格瑞洛，以及研究药物的作用，也进行了讨论。
Diabetes mellitus is a global pandemic, associated with a high burden of cardiovascular disease. There are multiple platelet derangements in patients with diabetes, and antiplatelet drugs remain the first-line agents for secondary prevention as well as for high-risk primary prevention among patients with diabetes. This review provides a summary of oral antiplatelet drug hypo-responsiveness in patients with diabetes, specifically aspirin and Clopidogrel resistance. Topics discussed include antiplatelet testing, definitions used to define hypo-response and resistance, its prevalence, association with clinical outcomes and strategies to mitigate resistance. The role of prasugrel and ticagrelor, as well as investigational agents, is also discussed.